Phase II Trial of Pembrolizumab and Trastuzumab in HER2-positive Esophagogastric Adenocarcinoma
A phase II trial is underway to evaluate the efficacy of a combination of pembrolizumab, trastuzumab, and FLOT in HER2-positive localized esophagogastric adenocarcinoma.